Indivior Pharmaceuticals (INDV)

The company’s core portfolio is based on buprenorphine, a medication widely used in medication-assisted treatment for opioid dependence. Its key products include Sublocade, a monthly extended-release buprenorphine injection designed to maintain therapeutic drug levels over an extended period, and Suboxone, a buprenorphine and naloxone sublingual film used in the treatment of opioid dependence. These products are prescribed by healthcare professionals and distributed through regulated pharmaceutical channels.

Indivior generates revenue from the development, manufacture, marketing, and sale of prescription medicines, primarily in the United States and other regulated markets. Its commercial strategy centers on access, clinical education, and support for providers treating patients with substance use disorders.

Beyond its established opioid dependence franchise, Indivior also participates in adjacent areas where addiction, overdose reversal, and serious mental illness intersect. The company operates in a highly regulated pharmaceutical market, where product approvals, reimbursement, patent protection, litigation, and public health policy can materially influence performance. Its distinctive position is its narrow therapeutic focus: rather than operating as a broad drugmaker, Indivior concentrates its research, commercial resources, and public-health messaging on improving treatment options for substance use disorders and related conditions.